Researchers from Peking University developed the iVAC vaccine that enhances immune response against cancer cells.
It blocks the PD-L1 protein used by tumors to evade detection and stimulates a strong immune attack.
Early trials showed significant tumor elimination in animals and lab studies.
This advancement could lead to more precise cancer therapies.
